Novartis AG ADR

Yahoo Finance • 23 hours ago

Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory

We came across a bullish thesis on Intellia Therapeutics, Inc. on Danny’s Substack by Danny Green. In this article, we will summarize the bulls’ thesis on NTLA. Intellia Therapeutics, Inc.'s share was trading at $12.48 as of February 18th.... Full story

Yahoo Finance • yesterday

Novartis (NVS) Announces Plans to Establish a New Radioligand Therapy Manufacturing Site in Denton, Texas

Novartis AG (NYSE:NVS) is one of the top gene therapy stocks to buy according to hedge funds. Novartis AG (NYSE:NVS) announced on February 25 plans to establish a new 46,000-square-foot radioligand therapy manufacturing site in Denton, Tex... Full story

Yahoo Finance • 2 days ago

Avidity (RNA) Moves Date for Shareholder Vote on Novartis Merger

Avidity Biosciences Inc. (NASDAQ:RNA) is one of 15 stocks with the biggest hedge fund momentum, after gaining 28 hedge fund holders during the fourth quarter of 2025. On February 23, Avidity Biosciences Inc. (NASDAQ:RNA) adjourned its spec... Full story

Yahoo Finance • 2 days ago

Analyst Optimistic on Terns (TERN) Citing Possible $4.8B Market for Upcoming Leukemia Drug

Terns Pharmaceuticals Inc. (NASDAQ:TERN) is one of 15 stocks with the biggest hedge fund momentum, after gaining 42 hedge fund holders during the fourth quarter of 2025. On February 9, Leerink Partners initiated coverage on Terns Pharmaceu... Full story

Yahoo Finance • 2 days ago

Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks rose late Friday afternoon, with the NYSE Health Care Index adding 1.3% and the S PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 days ago

Sector Update: Health Care Stocks Higher Friday Afternoon

Health care stocks rose Friday afternoon, with the NYSE Health Care Index and the State Street Healt PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 2 days ago

Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)

Novartis Pharma AG Remibrutinib, a highly selective oral BTKi, has potential to be first targeted therapy approved for CSU in Europe Improvements with remibrutinib observed as early as Week 1 in REMIX 1 & 2, with favorable safety profile... Full story

Yahoo Finance • 4 days ago

Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients

Novartis Pharma AG Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in US Site to serve patients in Southern US and add network capacity as RLT expands into earlier treatm... Full story

Yahoo Finance • 4 days ago

Novartis AG Enterprise Technology Report 2025: Digital Transformation Strategies, Innovation Programs, Technology Initiatives, Partnerships, Investment & Acquisition, Network Map

Company Logo Novartis presents key market opportunities through its focus on digital transformation, innovation programs, and strategic tech initiatives. It leverages partnerships, product launches, investments, and acquisitions to enhanc... Full story

Yahoo Finance • 4 days ago

Assessing Novartis (SWX:NOVN) Valuation After Positive Phase III Data And Upcoming Regulatory Milestones

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Novartis (SWX:NOVN) is back in the spotlight after a run of clinical updates, including Phase III data for remibrutini... Full story

Yahoo Finance • 5 days ago

Personalized Medicine Market Competitive Landscape Report 2025: Company Analysis, Company Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033

Company Logo Personalized Medicine Market Poised for Tremendous Growth by 2033The global personalized medicine market, valued at approximately US$ 585.53 billion in 2026, is projected to soar to nearly US$ 1.00 trillion by 2033. A report... Full story

Yahoo Finance • 5 days ago

New real‑world data reinforce earlier use of Pluvicto™ before chemotherapy in metastatic castration-resistant prostate cancer

Novartis Pharma AG In the real-world, Pluvicto™ showed 13.5 months median PFS in chemo-naïve patients with PSMA-positive mCRPC Real‑world evidence showed Pluvicto achieved longer PFS when initiated after one ARPI instead of multiple ARPI... Full story

Yahoo Finance • 7 days ago

Novartis: This Big Pharma Giant Could Be a Sleep‑at‑Night Core Holding for Decades

Novartis(NYSE: NVS) is a major Swiss drug company with a market capitalization of over $300 billion. Its focus areas are extensive, spanning oncology, immunology, neuroscience, respiratory care, and cardiovascular, renal, and metabolic dis... Full story

Yahoo Finance • 9 days ago

Trump Says Tariffs Drove Novartis' $23 Billion US Expansion

This article first appeared on GuruFocus. Novartis (NYSE:NVS) is once again intersecting with US trade policy after President Donald Trump said his tariff strategy may have influenced the Swiss drugmaker's decision to expand its domestic... Full story

Yahoo Finance • 9 days ago

Novartis to Sell 70.68% Stake in India Unit for 14.46 Billion Rupees

This article first appeared on GuruFocus. Novartis (NYSE:NVS) has agreed to divest its 70.68% stake in Novartis India Ltd. to a consortium of WaveRise Investments, ChrysCapital Fund X and Two Infinity Partners for 14.46 billion rupees, or... Full story

Yahoo Finance • 9 days ago

Novartis To Sell India Stake For $159 Million

This article first appeared on GuruFocus. Novartis (NYSE:NVS) is taking another step in its ongoing reshuffle, agreeing to sell its entire 70.68% stake in Novartis India for roughly $159 million to a private equity-led group. The buyers,... Full story

Yahoo Finance • 9 days ago

Stem Cell and Regenerative Therapy Markets, 2022-2025 & Forecast to 2030 Featuring Profiles of Leading Companies - Gilead Sciences, Novartis, Bristol-Myers Squibb, Organogenesis, MiMedx Group and More

Company Logo Technological advances and growing investments in stem cell research by private entities and governments enhance therapeutic production while reducing costs, fueling market growth and adoption Stem Cell and Regenerative Ther... Full story

Yahoo Finance • 9 days ago

Trump Says Tariffs Pushed Novartis to Expand Operations in US

Bloomberg (Bloomberg) -- President Donald Trump said his tariffs spurred Novartis AG to expand its US manufacturing footprint, following a meeting with the Swiss drugmaker’s chief executive Vas Narasimhan at the White House on Wednesday.... Full story

Yahoo Finance • 9 days ago

Novartis to exit Indian unit in $159 million deal

Feb 20 (Reuters) - Swiss drugmaker Novartis said on Friday ‌it would sell its ‌entire 70.68% stake in its listed ​Indian unit for 14.46 billion rupees ($159 million). The stake will be acquired by a ‌consortium of ⁠WaveRise Investments, C... Full story

Yahoo Finance • 10 days ago

Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D

TOKYO & BASKING RIDGE, N.J., February 20, 2026--(BUSINESS WIRE)--Daiichi Sankyo Company, Limited (TSE: 4568) has appointed John Tsai, MD to succeed Ken Takeshita, MD, who is stepping down as Global Head of R&D, effective April 1, 2026. Dr... Full story